Targeting Angiogenesis in Lung Cancer - Pitfalls in Drug Development

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806168

Citations 4

Authors

Wolfgang Hilbe

Christian Manegold

Andreas Pircher

Affiliations

Soon will be listed here.

Abstract

In non-small-cell lung cancer, anti-angiogenic strategies like bevacizumab have developed into standard treatment options. New anti-angiogenic drugs like tyrosine kinase inhibitors generated optimistic results in phase II trials, but failed to translate into positive results in phase III trials. In this overview some critical aspects of the biology of tumor angiogenesis and potential pitfalls of anti-angiogenic drug development are discussed. These include the design of clinical trials, dosage of investigational drugs or the choice of combinational drugs, the lack of validated biomarkers and the complexity of the patho-biology of tumor angiogenesis. Future trials should also direct attention to the role of cigarette smoke and the stage of the disease, which is investigated.

Citing Articles

Molecular Insights into Potential Contributions of Natural Polyphenols to Lung Cancer Treatment.

Zhou Q, Pan H, Li J Cancers (Basel). 2019; 11(10).

PMID: 31618955 PMC: 6826534. DOI: 10.3390/cancers11101565.

Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.

Pircher A, Wolf D, Heidenreich A, Hilbe W, Pichler R, Heidegger I Int J Mol Sci. 2017; 18(11).

PMID: 29088109 PMC: 5713261. DOI: 10.3390/ijms18112291.

DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma.

Zamay G, Ivanchenko T, Zamay T, Grigorieva V, Glazyrin Y, Kolovskaya O Mol Ther Nucleic Acids. 2017; 6:150-162.

PMID: 28325282 PMC: 5363495. DOI: 10.1016/j.omtn.2016.12.004.

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.

Pircher A, Johrer K, Kocher F, Steiner N, Graziadei I, Heidegger I Oncotarget. 2016; 7(15):20109-23.

PMID: 26956051 PMC: 4991441. DOI: 10.18632/oncotarget.7915.

References

Herbst R, Sun Y, Eberhardt W, Germonpre P, Saijo N, Zhou C . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11(7):619-26. PMC: 3225192. DOI: 10.1016/S1470-2045(10)70132-7. View

Brahimi-Horn M, Chiche J, Pouyssegur J . Hypoxia and cancer. J Mol Med (Berl). 2007; 85(12):1301-7. DOI: 10.1007/s00109-007-0281-3. View

Maltby S, Khazaie K, McNagny K . Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009; 1796(1):19-26. PMC: 2731828. DOI: 10.1016/j.bbcan.2009.02.001. View

De Boer R, Arrieta O, Yang C, Gottfried M, Chan V, Raats J . Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011; 29(8):1067-74. DOI: 10.1200/JCO.2010.29.5717. View

Blumenschein Jr G, Gatzemeier U, Fossella F, Stewart D, Cupit L, Cihon F . Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(26):4274-80. DOI: 10.1200/JCO.2009.22.0541. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Lee J, Hirsh V, Park K, Qin S, Blajman C, Perng R . Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012; 30(10):1114-21. DOI: 10.1200/JCO.2011.36.1709. View

Talmadge J, Fidler I . AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010; 70(14):5649-69. PMC: 4037932. DOI: 10.1158/0008-5472.CAN-10-1040. View

Jain R, Duda D, Willett C, Sahani D, Zhu A, Loeffler J . Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6(6):327-38. PMC: 3057433. DOI: 10.1038/nrclinonc.2009.63. View

10.

Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W . Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets. 2006; 6(4):271-94. DOI: 10.2174/156800906777441780. View

11.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

12.

Lara Jr P, Douillard J, Nakagawa K, von Pawel J, McKeage M, Albert I . Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(22):2965-71. DOI: 10.1200/JCO.2011.35.0660. View

13.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

14.

Potente M, Gerhardt H, Carmeliet P . Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146(6):873-87. DOI: 10.1016/j.cell.2011.08.039. View

15.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

16.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

17.

Fojo T, Parkinson D . Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. Clin Cancer Res. 2010; 16(24):5972-80. DOI: 10.1158/1078-0432.CCR-10-1277. View

18.

Resch T, Pircher A, Kahler C, Pratschke J, Hilbe W . Endothelial progenitor cells: current issues on characterization and challenging clinical applications. Stem Cell Rev Rep. 2011; 8(3):926-39. DOI: 10.1007/s12015-011-9332-9. View

19.

Goss G, Arnold A, Shepherd F, Dediu M, Ciuleanu T, Fenton D . Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2009; 28(1):49-55. DOI: 10.1200/JCO.2009.22.9427. View

20.

Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M . Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci. 2011; 12(10):7077-99. PMC: 3211028. DOI: 10.3390/ijms12107077. View